Cargando…

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy

BACKGROUND: The standard treatment of choice for malignant pleural mesothelioma is chemotherapy with pemetrexed and platinum, but the clinical outcome is poor. This study investigates the response to pemetrexed in a panel of eight mesothelioma cell lines and the clinical outcome for patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nutt, J E, Razak, A R A, O'Toole, K, Black, F, Quinn, A E, Calvert, A H, Plummer, E R, Lunec, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822938/ https://www.ncbi.nlm.nih.gov/pubmed/20051956 http://dx.doi.org/10.1038/sj.bjc.6605501

Ejemplares similares

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
por: Alì, G, et al.
Publicado: (2009)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate
por: Kim, S-E, et al.
Publicado: (2013)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
por: Patterson, M J, et al.
Publicado: (2014)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
por: Arnold, David T, et al.
Publicado: (2017)

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
por: Jacobson, B A, et al.
Publicado: (2009)

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
por: Pridgeon, S W, et al.
Publicado: (2011)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
por: Zaremba, T, et al.
Publicado: (2009)

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
por: O'Boyle, G, et al.
Publicado: (2013)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
por: McCloy, R A, et al.
Publicado: (2013)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma
por: Brown, N S, et al.
Publicado: (2005)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
por: Makhov, P, et al.
Publicado: (2014)

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
por: Griffiths, R W, et al.
Publicado: (2005)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Inhibition of γ-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells
por: Rasul, S, et al.
Publicado: (2009)

Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study
por: Martin, N K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_51gnb4dn5lu10ao2eilps9uuak